The landscape of oncological imaging is undergoing a paradigm shift with the US launch of Raidium Read. Developed by Raidium—an AI-native company bridging expertise between Paris and Silicon Valley—the platform is designed to replace legacy radiomics tools with a streamlined, AI-driven experience.
The impact is already evident at the Moffitt Cancer Center, where Raidium Read is being utilized for clinical trials and research. By leveraging a sophisticated foundation model, the system automates tumor tracking and reduces reader variability by up to three times, ensuring more consistent diagnostic outcomes.
While the platform is currently focused on research and clinical trials, Raidium expects FDA 510(k) clearance by the end of 2026, marking a critical step toward widespread clinical adoption. This move comes at a time when the integrity of medical research is under scrutiny; for instance, recent AI-driven audits have flagged hundreds of thousands of suspicious oncology studies produced by fraudulent paper mills. In this context, tools like Raidium Read provide a necessary layer of objective, data-driven precision to the fight against cancer.